Tumor Targeting by α(v)β(3)-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking

[Image: see text] Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles’ (NP) in vivo behavior is complex and the immune system’s role in their application remains elusive. At present, only passive-targeting nanoformulations have been clinically approved, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sofias, Alexandros Marios, Toner, Yohana C., Meerwaldt, Anu E., van Leent, Mandy M. T., Soultanidis, Georgios, Elschot, Mattijs, Gonai, Haruki, Grendstad, Kristin, Flobak, Åsmund, Neckmann, Ulrike, Wolowczyk, Camilla, Fisher, Elizabeth L., Reiner, Thomas, Davies, Catharina de Lange, Bjørkøy, Geir, Teunissen, Abraham J. P., Ochando, Jordi, Pérez-Medina, Carlos, Mulder, Willem J. M., Hak, Sjoerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392528/
https://www.ncbi.nlm.nih.gov/pubmed/32413260
http://dx.doi.org/10.1021/acsnano.9b08693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392528/
https://www.ncbi.nlm.nih.gov/pubmed/32413260
http://dx.doi.org/10.1021/acsnano.9b08693

Ejemplares similares